Safiglipron Phase 3 Trial: What the New Oral GLP-1 Data Shows

The safiglipron phase 3 trial found that a once-daily oral small-molecule <a href="https://glp1place.com/tools/compound/glp-1/”>GLP-1 receptor agonist substantially improved blood-glucose control in adults with early type 2 diabetes. During the 32-week placebo-controlled portion of OUTSTAND-1, safiglipron lowered glycated hemoglobin, or HbA1c, by 1.20 to 1.45 percentage points more than placebo across three dose groups. The tablet was studied without fasting or special food and water restrictions, which addresses a practical barrier linked to some oral GLP-1 medicines.

The findings are important, but they do not mean safiglipron is approved, interchangeable with <a href="https://glp1place.com/tools/compound/semaglutide/”>semaglutide, or proven to reduce heart attacks, kidney failure, or death. The study included 284 adults at 46 sites in China, lasted 32 weeks for its main comparison, and reported gastrointestinal adverse events in up to 73.6% of participants at the highest dose. The results establish safiglipron as a serious clinical-stage oral GLP-1 candidate, not a finished treatment option.

The peer-reviewed report was published in Nature Medicine on September 29, 2026. The study was sponsored by Jiangsu Hengrui Pharmaceuticals. Read the full OUTSTAND-1 publication for the complete methods, statistical analysis, and safety tables.

What is safiglipron?

Safiglipron is the proposed international nonproprietary name for HRS-7535. It is an investigational small-molecule agonist of the glucagon-like peptide-1 receptor, usually shortened to GLP-1 receptor agonist or GLP-1 RA. The compound is designed to activate the same broad receptor pathway as established GLP-1 medicines, but it is not a peptide.

That difference matters. Peptide medicines are chains of amino acids and can break down in the digestive tract. Small molecules have a different chemical structure and may be suitable for tablets that are easier to manufacture, store, and take. Safiglipron is being studied as a once-daily oral medicine without fasting or limited-water requirements around the dose.

Safiglipron is not the same compound as semaglutide, tirzepatide, or orforglipron. Semaglutide is a peptide GLP-1 receptor agonist. Tirzepatide activates both the GLP-1 and GIP receptors and is also peptide-based. Orforglipron is another oral small-molecule GLP-1 receptor agonist, but it has a different chemical structure and development program.

GLP-1 receptor activation can improve glucose control in several ways. It increases glucose-dependent insulin release, reduces inappropriate glucagon secretion, slows stomach emptying, and may reduce appetite. “Glucose-dependent” means the insulin effect is stronger when blood glucose is elevated, although safety still depends on the full treatment context and any other medicines used.

GLP1Place has previously covered the broader rise of oral GLP-1 medicines in the full oral GLP-1 lineup. Safiglipron adds new phase 3 data to this field, especially for people with early type 2 diabetes who may value a tablet without special meal timing.

How the safiglipron phase 3 trial was designed

OUTSTAND-1 was a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. These features help reduce common sources of bias. Randomization helps balance baseline differences between groups. Blinding limits the effect of expectations. A placebo group shows how much change might occur through background care, behavior, or trial participation alone.

The investigators screened 475 people at 46 clinical sites in China. After a placebo run-in period, 284 adults were randomly assigned to one of four groups:

Participants were 18 to 75 years old and had type 2 diabetes with HbA1c values from 7.0% to 10.0%. They were using diet and exercise alone at screening, although about one-third had previously used a glucose-lowering medicine and stopped it at least two months before screening. Mean baseline HbA1c was 7.95%, mean body weight was 77.5 kilograms, and median diabetes duration was 1.6 years.

All participants were Asian, and 33.1% were women. This makes the findings relevant to an important clinical setting, but it limits how confidently they can be applied to other ethnic groups, health systems, and stages of diabetes.

The primary endpoint was change in HbA1c from baseline to week 32. The trial then continued into a 20-week active-treatment extension. Participants originally assigned to placebo switched to 30 mg of safiglipron, so the extension was not a continued randomized placebo comparison.

What did the trial show for blood glucose?

The clearest finding was the reduction in HbA1c. At week 32, placebo-adjusted treatment differences were 1.22 percentage points for 30 mg, 1.20 percentage points for 60 mg, and 1.45 percentage points for 90 mg. All three comparisons were statistically significant, with P values below 0.0001.

In practical terms, least-squares mean HbA1c changes from baseline were minus 1.40 percentage points with 30 mg, minus 1.38 points with 60 mg, and minus 1.63 points with 90 mg. The placebo group changed by minus 0.18 points. Least-squares means are model-based estimates that account for the trial design and available follow-up data rather than simple unadjusted averages.

More participants also reached an HbA1c below 7.0% with safiglipron. Rates were 71.4% with 30 mg, 77.1% with 60 mg, and 77.8% with 90 mg, compared with 25.0% with placebo. The proportion reaching HbA1c of 6.5% or lower ranged from 58.6% to 68.1% across safiglipron groups, compared with 16.7% with placebo.

Fasting plasma glucose improved in all three dose groups. Placebo-adjusted differences were minus 1.58, minus 1.68, and minus 2.08 millimoles per liter for 30 mg, 60 mg, and 90 mg, respectively.

These results show clinically meaningful glucose-lowering activity for a monotherapy trial in early type 2 diabetes. The authors compared the findings with prior oral GLP-1 studies, including oral semaglutide and orforglipron. Such comparisons need caution because the populations, treatment durations, titration schedules, background therapy, and statistical methods were not identical.

Did safiglipron produce meaningful weight loss?

Weight loss occurred, but it was not the main focus of OUTSTAND-1. The trial enrolled adults with early type 2 diabetes rather than a dedicated obesity population, and its primary endpoint was glucose control.

At week 32, estimated placebo-adjusted changes in body weight were minus 0.65% with 30 mg, minus 2.23% with 60 mg, and minus 3.56% with 90 mg. The 30 mg result did not meet the prespecified statistical threshold in the fixed-sequence testing procedure, while the 60 mg and 90 mg comparisons were statistically significant.

These results are smaller than weight-loss percentages reported in many obesity-focused trials of higher-intensity GLP-1 or multi-receptor medicines. That does not show safiglipron is ineffective. It reflects the different goals of diabetes and obesity clinical development.

Weight outcomes also depend on baseline body mass index, diabetes duration, treatment duration, dose exposure, background diet, and whether weight loss is a primary or secondary objective. A diabetes trial with a mean baseline BMI of 27.8 kilograms per square meter should not be used to predict results from a future obesity trial.

Earlier phase 2 work with HRS-7535 examined adults with obesity without diabetes. That research provides context, but it should not be combined with phase 3 diabetes results as though both studies involved one continuous population. This phase 3 study is most informative about glucose control in early type 2 diabetes.

How convenient is the oral formulation?

The practical appeal of safiglipron is its administration format. The study evaluated a once-daily tablet without fasting or dietary restrictions. That could make treatment easier for people who find injections difficult or who struggle with rigid medication timing.

Oral semaglutide shows why this matters. Although it is a tablet, its peptide formulation has specific instructions for fasting and water intake. Those requirements are linked to the drug’s absorption. A small-molecule tablet may allow more flexible absorption, although instructions for any future approved product would depend on its own regulatory review.

Convenience is not the same as superiority. A tablet may be more acceptable for some people, while a once-weekly injection may be easier for others because it reduces the number of doses. The best format depends on efficacy, adverse effects, cost, access, patient preference, and long-term persistence.

The safiglipron study also used dose titration. Doses increased in 30-mg steps every four weeks. This gradual increase is common in incretin research because it may help participants adjust to gastrointestinal effects. Study titration schedules are research findings, not instructions for personal use.

Readers who want a general explanation of trial phases, endpoints, and placebo-adjusted results can review GLP1Place’s guide to reading a GLP-1 clinical trial.

What side effects were reported?

Gastrointestinal adverse events were the most common safety finding. During the 32-week core treatment period, they occurred in 44.3% of participants receiving 30 mg, 60.0% receiving 60 mg, and 73.6% receiving 90 mg. The placebo rate was 15.3%.

The publication states that most adverse events were mild or moderate and that many gastrointestinal events occurred during dose titration. This pattern is consistent with the broader GLP-1 class, but it does not make individual reactions predictable.

Adverse events led to treatment discontinuation in 1.4% of the 30-mg group, 2.9% of the 60-mg group, and 6.9% of the 90-mg group. No participants in the placebo group discontinued because of an adverse event. Gastrointestinal events accounted for most discontinuations in the safiglipron groups.

Serious adverse events occurred in 10.0% of the 30-mg group, 2.9% of the 60-mg group, and 6.9% of the 90-mg group, compared with 1.4% in the placebo group. This uneven pattern across doses is difficult to interpret in a trial of this size. The authors reported no deaths during the study.

These results support continued development, but they do not establish the full safety profile. A trial with 284 participants is too small to reliably detect rare events. Longer studies are needed to assess persistent gastrointestinal symptoms, gallbladder events, pancreatitis signals, diabetic retinopathy outcomes, kidney outcomes, cardiovascular events, and other potential risks.

Were there signs of kidney or cardiometabolic benefit?

The investigators reported favorable changes in several exploratory measures. At the 90-mg dose, triglycerides decreased by 13.2%, low-density lipoprotein cholesterol decreased by 8.9%, and total cholesterol decreased by 6.3% from baseline. Systolic blood pressure also fell relative to placebo in some dose groups.

Urinary albumin-to-creatinine ratio, or UACR, decreased in all three safiglipron groups. UACR is a laboratory measure of albumin leaking into urine, which can signal kidney stress or damage. Reported placebo-adjusted reductions were about 37% to 48%, depending on dose.

These findings are scientifically interesting, especially because earlier HRS-7535 research also examined diabetic kidney disease. However, lower albuminuria does not prove that a treatment prevents kidney failure. Surrogate markers can improve without producing the same effect on hard clinical outcomes.

The same caution applies to blood pressure and lipid changes. They may contribute to lower long-term risk, but OUTSTAND-1 was not designed or powered to establish fewer cardiovascular events. This trial alone cannot support conclusions about heart attack, stroke, hospitalization for heart failure, or mortality.

How does safiglipron compare with other oral GLP-1 candidates?

Safiglipron enters a rapidly expanding field of oral GLP-1 research. The main scientific divide is not simply tablet versus injection. Researchers are also comparing peptide and nonpeptide chemistry, receptor signaling, absorption, dosing frequency, weight effects, glucose effects, and tolerability.

GLP1Place has separately covered orforglipron and the phase 2 VCT220 program. Those articles should not be treated as evidence that the compounds are interchangeable. Each candidate has its own pharmacology, trial design, sponsor, dose range, and regulatory path.

The main lesson from safiglipron is that oral small-molecule GLP-1 development has moved beyond early proof of concept. A phase 3 study with significant glucose-lowering results shows that the category can produce clinically relevant effects in a larger confirmatory setting. It does not show that one compound has won the oral GLP-1 race.

What are the main limitations of the evidence?

The first limitation is the study population. Every participant was Asian and enrolled in China. Type 2 diabetes biology overlaps across populations, but body composition, diabetes duration, dietary patterns, treatment practices, and genetic factors can influence outcomes. Confirmation in broader multinational populations would strengthen external validity.

The second limitation is duration. The core placebo-controlled period lasted 32 weeks. That is long enough to evaluate HbA1c response, but not to establish durability over many years or detect uncommon safety events with confidence.

The third limitation is the lack of an active comparator. OUTSTAND-1 compared safiglipron with placebo, not with metformin, oral semaglutide, or orforglipron. Placebo-controlled efficacy is important, but clinicians and regulators also need evidence comparing a new medicine with available treatments.

The fourth limitation concerns clinical outcomes. HbA1c, fasting glucose, UACR, blood pressure, and weight are useful measures, but they are not cardiovascular or kidney-outcome trials. The study does not establish whether safiglipron reduces major adverse cardiovascular events or slows progression to kidney failure.

The fifth limitation is sponsorship. Jiangsu Hengrui Pharmaceuticals sponsored and funded the study and collaborated with academic authors on design, data collection, analysis, interpretation, and manuscript preparation. Industry-sponsored trials can be well conducted, but independent replication and transparent reporting remain important when assessing evidence.

Finally, the trial was not designed to answer the common consumer question about obesity treatment: how much weight an individual will lose. The data support a meaningful diabetes result. They should not be turned into a personal weight-loss forecast.

What happens next for safiglipron?

Next steps will likely include regulatory submissions, additional phase 3 studies, longer-term safety follow-up, and trials in broader diabetes populations. Important questions include how safiglipron performs when added to metformin or other background therapy, how it compares directly with oral semaglutide and other GLP-1 medicines, and whether its administration flexibility is preserved in final labeling.

Obesity-focused research is another likely area of interest. Earlier HRS-7535 studies examined weight reduction in adults with obesity without diabetes, but OUTSTAND-1 was not an obesity registration study. A dedicated obesity program would need to assess larger and longer weight changes, weight regain after treatment withdrawal, body composition, and tolerability at doses appropriate for chronic weight management.

Researchers will also need to clarify whether safiglipron’s kidney-marker findings translate into clinical kidney protection. The reported UACR reduction is an encouraging signal, but it remains exploratory in OUTSTAND-1. Outcome trials would be needed to determine whether the compound changes the risk of kidney decline, dialysis, or kidney-related hospitalization.

Regulatory agencies would also examine manufacturing quality, dose consistency, drug interactions, reproductive safety, liver and gallbladder findings, cardiovascular safety, and the full adverse-event profile. A positive phase 3 result is a major milestone, but it is only one part of a much larger approval process.

What the new data means for oral GLP-1 research

The safiglipron phase 3 trial strengthens the case that small-molecule GLP-1 receptor agonists can provide substantial glucose lowering in tablet form. The finding is especially notable because treatment was studied without the fasting and fluid restrictions associated with oral peptide semaglutide.

At the same time, the study shows that convenience does not remove the central trade-offs of GLP-1 pharmacology. Gastrointestinal adverse events increased as the dose rose. The highest dose produced the strongest glucose and weight results, but also the highest rate of gastrointestinal events and treatment discontinuation.

The study also shows why trial context matters. A diabetes trial should not be read as an obesity trial. A surrogate kidney marker should not be read as a kidney-outcome result. A statistically significant placebo comparison should not be read as proof of superiority over an approved medicine.

For researchers, safiglipron is now one of the more advanced oral small-molecule GLP-1 programs. For readers following the metabolic-drug pipeline, the key questions now extend beyond whether a tablet can activate the GLP-1 receptor. They include how reliably the drug works across populations, how well people tolerate it over years, whether it improves hard clinical outcomes, and how its convenience affects long-term persistence.

For now, the evidence supports a measured conclusion: safiglipron produced strong phase 3 glucose-control data in early type 2 diabetes, with a promising administration profile and a familiar dose-related gastrointestinal burden. It remains investigational, and future trials will show whether those advantages hold up in broader testing.

Frequently asked questions

What is safiglipron?

Safiglipron is the proposed international nonproprietary name for HRS-7535, an investigational once-daily oral small-molecule GLP-1 receptor agonist developed for metabolic disease research. It is structurally different from peptide drugs such as semaglutide and from other oral small-molecule candidates such as orforglipron.

What did the safiglipron phase 3 trial find?

In the 32-week placebo-controlled period, safiglipron reduced HbA1c by 1.20 to 1.45 percentage points more than placebo across the 30 mg, 60 mg, and 90 mg groups. The 60 mg and 90 mg groups also produced statistically significant weight reductions versus placebo.

Was safiglipron tested for weight loss?

The OUTSTAND-1 trial primarily studied blood-glucose control in adults with early type 2 diabetes. Weight was a secondary outcome. Placebo-adjusted weight differences ranged from 0.65% at 30 mg to 3.56% at 90 mg after 32 weeks, which is more modest than results from obesity-focused trials.

Does safiglipron require fasting or water restrictions?

The study evaluated once-daily oral safiglipron without fasting or dietary restrictions. This is a potential convenience advantage over oral peptide semaglutide, which has specific administration requirements. The trial does not prove that every future formulation or approved label would use identical instructions.

What were the most common side effects?

Gastrointestinal adverse events were the most common. They occurred in 44.3% of participants receiving 30 mg, 60.0% receiving 60 mg, and 73.6% receiving 90 mg, compared with 15.3% receiving placebo. Most events were mild or moderate, but discontinuations increased at higher doses.

Is safiglipron FDA approved?

No. The September 29, 2026 publication reports clinical-trial findings, not a U.S. approval. The trial was conducted at 46 sites in China, and additional regulatory submissions, comparative trials, and longer-term evidence would be needed before approval decisions.